Literature DB >> 27872127

Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions.

Claudio Vernieri1,2, Stefano Casola2, Marco Foiani2,3, Filippo Pietrantonio4, Filippo de Braud4,3, Valter Longo5,6.   

Abstract

Most tumors display oncogene-driven reprogramming of several metabolic pathways, which are crucial to sustain their growth and proliferation. In recent years, both dietary and pharmacologic approaches that target deregulated tumor metabolism are beginning to be considered for clinical applications. Dietary interventions exploit the ability of nutrient-restricted conditions to exert broad biological effects, protecting normal cells, organs, and systems, while sensitizing a wide variety of cancer cells to cytotoxic therapies. On the other hand, drugs targeting enzymes or metabolites of crucial metabolic pathways can be highly specific and effective, but must be matched with a responsive tumor, which might rapidly adapt. In this review, we illustrate how dietary and pharmacologic therapies differ in their effect on tumor growth, proliferation, and metabolism and discuss the available preclinical and clinical evidence in favor of or against each of them. We also indicate, when appropriate, how to optimize future investigations on metabolic therapies on the basis of tumor- and patient-related characteristics. SIGNIFICANCE: To our knowledge, this is the first review article that comprehensively analyzes the preclinical and preliminary clinical experimental foundations of both dietary and pharmacologic metabolic interventions in cancer therapy. Among several promising therapies, we propose treatment personalization on the basis of tumor genetics, tumor metabolism, and patient systemic metabolism.Cancer Discov; 6(12); 1315-33. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27872127      PMCID: PMC5140697          DOI: 10.1158/2159-8290.CD-16-0615

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  179 in total

1.  Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate.

Authors:  Preethi Korangath; Wei Wen Teo; Helen Sadik; Liangfeng Han; Noriko Mori; Charlotte M Huijts; Flonne Wildes; Santosh Bharti; Zhe Zhang; Cesar A Santa-Maria; Hualing Tsai; Chi V Dang; Vered Stearns; Zaver M Bhujwalla; Saraswati Sukumar
Journal:  Clin Cancer Res       Date:  2015-03-26       Impact factor: 12.531

2.  Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study.

Authors:  Pamela T Soliman; Qian Zhang; Russell R Broaddus; Shannon N Westin; David Iglesias; Mark F Munsell; Rosemarie Schmandt; Melinda Yates; Lois Ramondetta; Karen H Lu
Journal:  Gynecol Oncol       Date:  2016-10-13       Impact factor: 5.482

3.  2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling.

Authors:  Xudong Fu; Randall M Chin; Laurent Vergnes; Heejun Hwang; Gang Deng; Yanpeng Xing; Melody Y Pai; Sichen Li; Lisa Ta; Farbod Fazlollahi; Chuo Chen; Robert M Prins; Michael A Teitell; David A Nathanson; Albert Lai; Kym F Faull; Meisheng Jiang; Steven G Clarke; Timothy F Cloughesy; Thomas G Graeber; Daniel Braas; Heather R Christofk; Michael E Jung; Karen Reue; Jing Huang
Journal:  Cell Metab       Date:  2015-07-16       Impact factor: 27.287

4.  PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine.

Authors:  Brian P Lieberman; Karl Ploessl; Limin Wang; Wenchao Qu; Zhihao Zha; David R Wise; Lewis A Chodosh; George Belka; Craig B Thompson; Hank F Kung
Journal:  J Nucl Med       Date:  2011-11-15       Impact factor: 10.057

Review 5.  Current treatment strategies for inhibiting mTOR in cancer.

Authors:  Francesca Chiarini; Camilla Evangelisti; James A McCubrey; Alberto M Martelli
Journal:  Trends Pharmacol Sci       Date:  2014-12-11       Impact factor: 14.819

6.  Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression.

Authors:  Sebastian Brandhorst; Min Wei; Saewon Hwang; Todd E Morgan; Valter D Longo
Journal:  Exp Gerontol       Date:  2013-02-21       Impact factor: 4.032

7.  Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.

Authors:  Linda J Nicholson; Paul R Smith; Louise Hiller; Peter W Szlosarek; Christopher Kimberley; Jalid Sehouli; Dominique Koensgen; Alexander Mustea; Peter Schmid; Tim Crook
Journal:  Int J Cancer       Date:  2009-09-15       Impact factor: 7.396

Review 8.  Arginine metabolism: boundaries of our knowledge.

Authors:  Sidney M Morris
Journal:  J Nutr       Date:  2007-06       Impact factor: 4.798

9.  Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer.

Authors:  Brian M Wolpin; Jeffrey A Meyerhardt; Andrew T Chan; Kimmie Ng; Jennifer A Chan; Kana Wu; Michael N Pollak; Edward L Giovannucci; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

10.  Measuring the biological effect of presurgical metformin treatment in endometrial cancer.

Authors:  V N Sivalingam; S Kitson; R McVey; C Roberts; P Pemberton; K Gilmour; S Ali; A G Renehan; H C Kitchener; E J Crosbie
Journal:  Br J Cancer       Date:  2016-01-21       Impact factor: 7.640

View more
  56 in total

1.  Butyrate Suppresses the Proliferation of Colorectal Cancer Cells via Targeting Pyruvate Kinase M2 and Metabolic Reprogramming.

Authors:  Qingran Li; Lijuan Cao; Yang Tian; Pei Zhang; Chujie Ding; Wenjie Lu; Chenxi Jia; Chang Shao; Wenyue Liu; Dong Wang; Hui Ye; Haiping Hao
Journal:  Mol Cell Proteomics       Date:  2018-05-08       Impact factor: 5.911

Review 2.  Caregiver Well-being and the Quality of Cancer Care.

Authors:  Kristin Litzelman
Journal:  Semin Oncol Nurs       Date:  2019-06-20       Impact factor: 2.315

3.  Starving leukemia to induce differentiation.

Authors:  Chia-Wei Cheng; Ömer H Yilmaz
Journal:  Nat Med       Date:  2017-01-06       Impact factor: 53.440

Review 4.  Anticancer effects of the microbiome and its products.

Authors:  Laurence Zitvogel; Romain Daillère; María Paula Roberti; Bertrand Routy; Guido Kroemer
Journal:  Nat Rev Microbiol       Date:  2017-05-22       Impact factor: 60.633

Review 5.  Systems Chronotherapeutics.

Authors:  Annabelle Ballesta; Pasquale F Innominato; Robert Dallmann; David A Rand; Francis A Lévi
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

Review 6.  Transferrin receptor 1 in cancer: a new sight for cancer therapy.

Authors:  Ying Shen; Xin Li; Dandan Dong; Bin Zhang; Yanru Xue; Peng Shang
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

7.  Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis.

Authors:  Claudio Vernieri; Fabio Galli; Laura Ferrari; Paolo Marchetti; Sara Lonardi; Evaristo Maiello; Rosario V Iaffaioli; Maria G Zampino; Alberto Zaniboni; Sabino De Placido; Maria Banzi; Azzurra Damiani; Daris Ferrari; Gerardo Rosati; Roberto F Labianca; Paolo Bidoli; Giovanni L Frassineti; Mario Nicolini; Lorenzo Pavesi; Maria C Tronconi; Angela Buonadonna; Sabrina Ferrario; Giovanni Lo Re; Vincenzo Adamo; Emiliano Tamburini; Mario Clerico; Paolo Giordani; Francesco Leonardi; Sandro Barni; Andrea Ciarlo; Luigi Cavanna; Stefania Gori; Saverio Cinieri; Marina Faedi; Massimo Aglietta; Maria Antista; Katia F Dotti; Francesca Galli; Maria Di Bartolomeo
Journal:  Oncologist       Date:  2019-01-03

8.  mTORC2 links growth factor signaling with epigenetic regulation of iron metabolism in glioblastoma.

Authors:  Kenta Masui; Mio Harachi; Shiro Ikegami; Huijun Yang; Hiromi Onizuka; William H Yong; Timothy F Cloughesy; Yoshihiro Muragaki; Takakazu Kawamata; Nobutaka Arai; Takashi Komori; Webster K Cavenee; Paul S Mischel; Noriyuki Shibata
Journal:  J Biol Chem       Date:  2019-11-11       Impact factor: 5.157

Review 9.  Shining a light on metabolic vulnerabilities in non-small cell lung cancer.

Authors:  Catríona M Dowling; Hua Zhang; Tríona Ní Chonghaile; Kwok-Kin Wong
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-10-29       Impact factor: 10.680

10.  Effect of Starvation in Reversing Cancer Chemoresistance Based on Drug-Resistance Detection by Dextran Nanoparticles.

Authors:  Chenglong Wang; Xuzhu Gao; Fanchen Wang; Wencai Guan; Hongjing Dou; Guoxiong Xu
Journal:  Int J Nanomedicine       Date:  2020-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.